[HTML][HTML] PD-L1, TMB, MSI, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer
A Rizzo, AD Ricci, G Brandi - Cancers, 2021 - mdpi.com
Simple Summary Over the last decade, immune checkpoint inhibitors (ICIs) targeting
programmed death 1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T …
programmed death 1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T …
[HTML][HTML] The role of exosomes and their applications in cancer
Y Zhou, Y Zhang, H Gong, S Luo, Y Cui - International journal of …, 2021 - mdpi.com
Exosomes are very small extracellular vesicles secreted by multiple cell types and are
extensively distributed in various biological fluids. Recent research indicated that exosomes …
extensively distributed in various biological fluids. Recent research indicated that exosomes …
Recent advances of immunotherapy for biliary tract cancer
A Rizzo, AD Ricci, G Brandi - Expert review of gastroenterology & …, 2021 - Taylor & Francis
Introduction: Biliary tract cancer (BTC) is a heterogeneous group of aggressive malignancies
comprising intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder …
comprising intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder …
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer
A Rizzo, AD Ricci, G Brandi - Expert opinion on investigational …, 2021 - Taylor & Francis
Introduction: The prognosis of patients with advanced biliary tract cancer (BTC) remains
dismal, with a 5-year overall survival rate of less than 10%. Although immune checkpoint …
dismal, with a 5-year overall survival rate of less than 10%. Although immune checkpoint …
[HTML][HTML] Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma
A Rizzo, G Brandi - Cancer treatment and research communications, 2021 - Elsevier
Hepatocellular carcinoma (HCC) represents the most commonly diagnosed liver cancer
worldwide, and the overall survival of patients with unresectable disease is poor. In the last …
worldwide, and the overall survival of patients with unresectable disease is poor. In the last …
Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: Evidence to date and future perspectives
A Rizzo, AD Ricci, G Brandi - Expert Opinion on Investigational …, 2021 - Taylor & Francis
ABSTRACT Introduction Biliary tract cancers (BTCs) are poor prognosis malignancies
usually classified in intrahepatic cholangiocarcinoma (iCCA), extrahepatic …
usually classified in intrahepatic cholangiocarcinoma (iCCA), extrahepatic …
[HTML][HTML] First-line chemotherapy in advanced biliary tract cancer ten years after the ABC-02 trial:“And yet it moves!”
A Rizzo, G Brandi - Cancer treatment and research communications, 2021 - Elsevier
Biliary tract cancers (BTCs) include a heterogeneous group of highly aggressive
hepatobiliary malignancies, representing the 3% of all gastrointestinal cancers and the …
hepatobiliary malignancies, representing the 3% of all gastrointestinal cancers and the …
[HTML][HTML] Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma
A Rizzo, AD Ricci, G Brandi - Cancer Treatment and Research …, 2021 - Elsevier
Cholangiocarcinoma (CCA) includes a heterogeneous group of malignancies with limited
treatment options. Despite recent advances in medical oncology, the prognosis of CCA …
treatment options. Despite recent advances in medical oncology, the prognosis of CCA …
[HTML][HTML] Mutational spectrum and precision oncology for biliary tract carcinoma
Background: The genomic spectrum of biliary tract carcinoma (BTC) has been characterized
and is associated with distinct anatomic and etiologic subtypes, yet limited studies have …
and is associated with distinct anatomic and etiologic subtypes, yet limited studies have …
Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer
A Rizzo, G Brandi - Expert Review of Gastroenterology & …, 2021 - Taylor & Francis
Introduction: Unfortunately, potentially curative surgical resection is possible in
approximately the 25% of biliary tract cancer (BTC) patients at diagnosis, and even following …
approximately the 25% of biliary tract cancer (BTC) patients at diagnosis, and even following …